Zhong Nanshan: Both independent innovation and the combination of science and technology economy

received the reply, I was very happy, because
Total
made a very loud statement that innovation is the first driving force for development, and technology is a powerful weapon to overcome difficulties. As one of the writers, Zhong Nanshan, a
, was encouraged.
letter to
General
the United States at the time, there was a major sense that our country was still subject to human control in many key core areas. Under such pressure, we must promote independent innovation, but also promote the integration of industry, science and research, that is, science and technology to be integrated with the economy. Zhong Nanshan said of the original intention of writing a letter.
future, we must work innovation, but also combine science and technology with the economy well, so that we can truly realize what the
calls 'technology is a powerful weapon to overcome difficulties'. "In addition to the excitement, Zhong Nanshan has a clearer understanding of the future direction of the work of science and technology workers.
that's what Zhong Nanshan said, and that's what he did. On June 16th, he participated in the Forum on Severe Lung Cancer in Guangzhou, on June 17th, he was busy in the National Key Laboratory throughout the day, and on the morning of June 18th, Zhong Nanshan connected with the University of Sydney, Australia, at the First Hospital affiliated with Guangzhou Medical University to introduce China's experience in the fight against the new coronavirus
, and answered questions from the University of Sydney and the Australian and Chinese media. Recently, Guangzhou Medical University affiliated with the first hospital announced his trip in recent days, with "non-stop" to describe the slightest.
in the fight against the new crown pneumonia
, Zhong Nanshan, who has always focused on innovation, has strengthened his thinking. "This is fully reflected in the whole anti-epidemic process, because the new crown pneumonia has not been encountered around the world, how it occurs, how to infect, what is the route of infection, and what causes it to become ill, how to diagnose, how to treat, how to prevent, are new things, so it is very much necessary for science and technology workers to use their creativity, innovative spirit to deal with." Zhong Nanshan said.
" I am located in Guangzhou Medical University affiliated with the first hospital, received almost all of Guangzhou's critically ill patients, the most serious cases, we rescued 19, May 27 all cleared. In this anti-epidemic, we do not have the former car, we also do not have foreign reference information, are their own touch stone across the river. Many medical personnel, many scientific and technological workers, in prevention, upstream prevention and control strategy, early diagnosis, etc. , have made some achievements. Mr Zhong said.
statistics, as of early May this year, the world's research articles on neo-crown pneumonia, published in more well-known journals a total of 2,151 articles. Zhong Nanshan introduced, of which China published 650 articles, almost a third, and many are published in top magazines. "These articles provide a very good experience in guiding how to prevent and control the world, and in some ways guide them." He said.
we have also developed methods - Chinese methods, especially those to prevent patients from developing from general to severe and from critical to critical. In this process, there are some Chinese medicine also played a very good role, one or two of which have been recognized by the international academic community, so this Chinese medicine to the world has also played a great role. "Zhong Nanshan affirmed the role of Chinese medicine in curbing the outbreak of neo-crown pneumonia.
about the progress of vaccine research and development of public concern, Zhong Nanshan made it clear that China's vaccine research progress in the world is the first echelon. "Whether it's an RNA vaccine or an all-virus inactivated vaccine, now that we have five vaccines that are in Phase II clinical trials, we're not slow at all." Zhong Nanshan said.